Key result
Metformin reduces cardiac injury markers and oxidative stress while improving glycemic control in diabetic rats.
Why the study?
The study was conducted to evaluate the effect of metformin monotherapy on body weight, glycaemic control, lipid profile, oxidative stress, and cardiac injury in type 2 diabetic rats.
Does metformin improve cardiac injury, oxidative stress, and metabolic parameters in adult male albino rats with type 2 diabetes?
Population
Adult male albino rats with type 2 diabetes
Comparison
Diabetes + Metformin vs diabetic and control groups
Design
Animal experimental study
Follow-up
28 days
Authors
Loading...
Hypothesis-generating in diabetic rat models; leaves open translation to human diabetic cardiomyopathy.
Does metformin improve cardiac injury, oxidative stress, and metabolic parameters in adult male albino rats with type 2 diabetes?
Metformin monotherapy ameliorates diabetic cardiomyopathy, improves glycemic control, and reduces oxidative stress in a rat model of type 2 diabetes.
Kotb et al. (2022) studied Type 2 diabetes with diabetic cardiomyopathy. Metformin vs. Diabetic control group was evaluated on Body weight, glycaemic control, lipid profile, oxidative stress and cardiac injury. Metformin treatment in diabetic rats significantly decreased body weight, glucose, cardiac injury markers, and oxidative stress while improving insulin levels and cardiac histopathology.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: